Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825943 | 0.88 | AURKA (0.43) | GAAMAPK8TSHRHTTL3MBTL1 | |
| SCHEMBL4825960 | 0.88 | AURKA (0.43) | GAAMAPK8TSHRHTTL3MBTL1 | |
| SCHEMBL5389768 | 0.86 | PDE4A (0.45) | GAAMAPK8 | |
| SCHEMBL5446252 | 0.86 | PDE4A (0.45) | GAAMAPK8 | |
| SCHEMBL4823611 | 0.84 | GAA (0.41) | GAAMAPK8TSHRHTTL3MBTL1 | |
| SCHEMBL5397365 | 0.83 | GAA (0.42) | GAAMAPK8 | |
| SCHEMBL14223448 | 0.81 | GAA (0.39) | GAAMAPK8TSHRHTTL3MBTL1 | |
| SCHEMBL5392043 | 0.80 | GAA (0.44) | GAAMAPK8 | |
| SCHEMBL4831580 | 0.80 | GAA (0.38) | GAAMAPK8 | |
| SCHEMBL5397797 | 0.80 | PDE4A (0.47) | GAAMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252158-B1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-04-20 | — | — | EP | claimed |
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PDE4B, PDE4A, NOX4 | GAA 532/4885MAPK8 1820/4885TSHR 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.